Identification of key immune genes related to lymphatic metastasis of papillary thyroid cancer via bioinformatics analysis and experimental validation

Objective The current research aimed to development and validation in signature immune genes for lymphatic metastasis in papillary thyroid cancer (PTC). Method Weighted correlation network analysis (WGCNA) was performed to identify genes closely correlated with lymphatic metastasis in PTC from TCGA database. Information on immune-related genes (IRGs) was obtained from the ImmPort database. Crossover genes were used with the R package clusterProfiler for Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment. Key genes in the protein–protein interaction network of cross-targets were obtained using Cytoscape. Lasso and Random Forest (RF) models were utilized to identify pivotal genes. We constructed a nomogram based on the hub genes. The correlation between hub genes and immune cell infiltration was explored. We collected and assessed clinical samples via immunohistochemistry to detect the expression of hub genes. Result In total, 122 IRGs were correlated with lymphatic metastases from PTC. There are 10 key IRGs in the protein–protein interaction network. Then, three hub genes including PTGS2, MET, and ICAM1 were established using the LASSO and RF models. The expression of these hub genes was upregulated in samples collected from patients with lymphatic metastases. The average area under the curve of the model reached 0.83 after a 10-fold and 200-time cross-validation, which had a good prediction ability. Immuno-infiltration analysis showed that the three hub genes were significantly positively correlated with resting dendritic cells and were negatively correlated with activated natural cells, monocytes, and eosinophils. Immunohistochemistry results revealed that lymph node metastasis samples had a higher expression of the three hub genes than non-metastasis samples. Conclusion Via bioinformatics analysis and experimental validation, MET and ICAM1 were found to be upregulated in lymph node metastasis from papillary thyroid carcinoma. Further, the two hub genes were closely correlated with activated natural killer cells, monocytes, resting dendritic cells, and eosinophils. Therefore, these two genes may be novel molecular biomarkers and therapeutic targets in lymph node metastasis from papillary thyroid carcinoma.

[1]  Byung-Joo Lee,et al.  Machine learning-based prediction model using clinico-pathologic factors for papillary thyroid carcinoma recurrence , 2021, Scientific Reports.

[2]  Z. Dai,et al.  Global Burden of Thyroid Cancer From 1990 to 2017 , 2020, JAMA network open.

[3]  S. Fagerholm,et al.  Cell Adhesion Molecules and Their Roles and Regulation in the Immune and Tumor Microenvironment , 2019, Front. Immunol..

[4]  S. Hugues,et al.  Tumor-Associated Lymphatic Vessel Features and Immunomodulatory Functions , 2019, Front. Immunol..

[5]  O. Hashim,et al.  Papillary Thyroid Cancer: Genetic Alterations and Molecular Biomarker Investigations , 2019, International journal of medical sciences.

[6]  S. Masoodi,et al.  RET/PTC Gene Rearrangements in Thyroid Carcinogenesis: Assessment and Clinico-Pathological Correlations , 2018, Pathology & Oncology Research.

[7]  Z. Y. Zhang,et al.  HPV16 E6 Promotes Breast Cancer Proliferation via Upregulation of COX-2 Expression , 2017, BioMed research international.

[8]  Yaping Li,et al.  IR-780-loaded polymeric micelles enhance the efficacy of photothermal therapy in treating breast cancer lymphatic metastasis in mice , 2017, Acta Pharmacologica Sinica.

[9]  Wei Chen,et al.  CCL21/CCR7 interaction promotes cellular migration and invasion via modulation of the MEK/ERK1/2 signaling pathway and correlates with lymphatic metastatic spread and poor prognosis in urinary bladder cancer , 2017, International journal of oncology.

[10]  M. Trovato,et al.  Hepatocyte Growth Factor/C-Met Axis in Thyroid Cancer: From Diagnostic Biomarker to Therapeutic Target , 2017, Biomarker insights.

[11]  Kecheng Zhang,et al.  Intercellular adhesion molecule 1 is a sensitive and diagnostically useful immunohistochemical marker of papillary thyroid cancer (PTC) and of PTC-like nuclear alterations in Hashimoto's thyroiditis , 2016, Oncology letters.

[12]  Ash A. Alizadeh,et al.  Robust enumeration of cell subsets from tissue expression profiles , 2015, Nature Methods.

[13]  A. Lewiński,et al.  Assessment of cyclooxygenase-1 and 2 gene expression levels in chronic autoimmune thyroiditis, papillary thyroid carcinoma and nontoxic nodular goitre , 2014, Thyroid Research.

[14]  D. Del Bufalo,et al.  Papillary carcinoma of the thyroid: high expression of COX-2 and low expression of KAI-1/CD82 are associated with increased tumor invasiveness. , 2013, Thyroid : official journal of the American Thyroid Association.

[15]  S. Horvath,et al.  WGCNA: an R package for weighted correlation network analysis , 2008, BMC Bioinformatics.

[16]  Z. Jehan,et al.  Genome‐wide expression analysis of Middle Eastern papillary thyroid cancer reveals c‐MET as a novel target for cancer therapy , 2007, The Journal of pathology.

[17]  P. Vitti,et al.  Lymphocyte and immature dendritic cell infiltrates in differentiated, poorly differentiated, and undifferentiated thyroid carcinoma. , 2007, Thyroid : official journal of the American Thyroid Association.

[18]  Koichi Ito,et al.  Lymph Node Metastasis From 259 Papillary Thyroid Microcarcinomas: Frequency, Pattern of Occurrence and Recurrence, and Optimal Strategy for Neck Dissection , 2003, Annals of surgery.

[19]  H. Fujita,et al.  Cyclooxygenase‐2 promotes prostate cancer progression , 2002, The Prostate.

[20]  E. Fearon,et al.  Cancer progression , 1999, Current Biology.

[21]  F. Trimarchi,et al.  Expression of the hepatocyte growth factor and c-met in normal thyroid, non-neoplastic, and neoplastic nodules. , 1998, Thyroid : official journal of the American Thyroid Association.

[22]  R. Raz,et al.  The role of s100-positive dendritic cells in the prognosis of papillary thyroid carcinoma. , 2013, American journal of clinical pathology.

[23]  A. Cossu,et al.  Intercellular adhesion molecule-1 (ICAM-1) immunoreactivity in well-differentiated thyroid papillary carcinomas. , 1996, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.